Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEVETIRACETAM IN SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Adjunctive therapy in the treatment of partial-onset seizures in adults and children ≥1 month,Adjunctive therapy in myoclonic seizures in adults and children ≥12 years with juvenile myoclonic epilepsy,Adjunctive therapy in primary generalized tonic-clonic seizures in adults and children ≥6 years with idiopathic generalized epilepsy
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
500-1500 mg IV every 12 hours; initial dose 1000 mg/day, titrate by 1000 mg/day every 2 weeks up to 3000 mg/day.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
6-8 hours in adults; prolonged in elderly (10-11 h) and renal impairment (up to 25 h in ESRD)
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Levetiracetam is primarily eliminated renally; approximately 24% undergoes metabolism by hydrolysis of the acetamide group, not dependent on CYP450 enzymes.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
66% renal (unchanged), 27% as inactive metabolite (UCB L057) via renal; <1% fecal
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
<10% (negligible); not bound to albumin or alpha-1-acid glycoprotein
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
0.5-0.7 L/kg; approximates total body water, indicating extensive distribution into tissues and CNS
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
IV: 100%; Oral: 100% (rapid and complete absorption)
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
Cr Cl >80 m L/min: 500-1500 mg every 12h; Cr Cl 50-80: 500-1000 mg every 12h; Cr Cl 30-50: 250-750 mg every 12h; Cr Cl <30: 250-500 mg every 12h; ESRD: 500-1000 mg every 24h with 250-500 mg supplement post-dialysis.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Severe impairment (Child-Pugh C): reduce maintenance dose by 50%.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
1 month to <6 months: 7 mg/kg/dose IV every 12h; 6 months to <4 years: 10 mg/kg/dose IV every 12h; 4 to <16 years: 10 mg/kg/dose IV every 12h up to 30 mg/kg/day. Maximum 3000 mg/day.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Initiate at 500 mg twice daily, titrate slowly due to age-related renal function decline; adjust dose per creatinine clearance.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
No FDA black box warnings.
None
Behavioral and psychiatric symptoms: aggression, agitation, anger, anxiety, depression, mood swings, psychosis, suicidal ideation,Somnolence and fatigue,Serious dermatological reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis),Hematologic abnormalities (e.g., decreased white blood cell counts),Hypersensitivity reactions including angioedema,Renal impairment requires dose adjustment
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hypersensitivity to levetiracetam or any component of the formulation
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
No significant food interactions. Levetiracetam can be taken with or without food. Avoid excessive alcohol consumption as it may increase CNS depression.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Levetiracetam is associated with an increased risk of major congenital malformations, particularly neural tube defects, when used during the first trimester. Exposure in the second and third trimesters may lead to fetal growth restriction and neurodevelopmental effects. The risk appears dose-dependent.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Levetiracetam is excreted into human breast milk with a milk-to-plasma (M/P) ratio of approximately 1.0. Infant exposure is estimated to be 1-2% of the maternal weight-adjusted dose. No adverse effects have been reported in breastfed infants, but caution is recommended.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
Pregnancy may decrease levetiracetam plasma concentrations by up to 40-60% due to increased clearance. Dose adjustment is often required: monitor serum trough levels and increase dose as needed to maintain therapeutic levels. Postpartum, monitor for potential dose reduction.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
Monitor for behavioral and psychiatric symptoms, especially in pediatric patients. Infusion rate should not exceed 5 mg/kg/min. Risk of suicidal thoughts and behavior. Caution in renal impairment; adjust dose based on creatinine clearance. Levetiracetam is not significantly protein-bound and has minimal drug interactions. May cause somnolence, dizziness, and coordination difficulties.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
Report any new or worsening depression, agitation, hostility, or suicidal thoughts immediately.,Do not drive or operate heavy machinery until you know how levetiracetam affects you; it may cause dizziness or sleepiness.,If you miss a dose, take it as soon as you remember unless it is almost time for your next dose; do not double dose.,Do not stop taking levetiracetam abruptly; this can increase seizure frequency.,Inform all healthcare providers that you take levetiracetam, especially before surgery or emergency treatment.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Levetiracetam, an antiepileptic drug, may potentiate the sedative effects of pramipexole, a dopamine agonist used for Parkinson's disease and restless legs syndrome. This additive pharmacodynamic interaction results in increased central nervous system depression, leading to enhanced drowsiness, dizziness, and impaired psychomotor function. Clinically, patients may experience excessive sedation, reduced alertness, and an increased risk of falls or accidents, particularly during treatment initiation or dose adjustments."
"Butorphanol, a mixed agonist-antagonist opioid, and levetiracetam, an antiepileptic, both lower the seizure threshold and can cause central nervous system (CNS) depression. Coadministration may result in additive CNS depression, leading to excessive sedation, respiratory depression, and an increased risk of seizures, especially in patients with epilepsy or head trauma. Clinically, this combination can provoke breakthrough seizures and worsen cognitive and psychomotor impairment."
"Thiothixene, a typical antipsychotic, can lower the seizure threshold, increasing the risk of convulsions, particularly in patients with epilepsy. Levetiracetam, an anticonvulsant, may be less effective if seizure threshold is reduced, potentially leading to breakthrough seizures. Additionally, both drugs can cause CNS depression, leading to additive sedation, dizziness, and impaired cognitive function."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LEVETIRACETAM IN SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
LEVETIRACETAM IN SODIUM CHLORIDE is a Electrolyte that works by Levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEVETIRACETAM IN SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEVETIRACETAM IN SODIUM CHLORIDE is: 500-1500 mg IV every 12 hours; initial dose 1000 mg/day, titrate by 1000 mg/day every 2 weeks up to 3000 mg/day.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEVETIRACETAM IN SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEVETIRACETAM IN SODIUM CHLORIDE is classified as Category A/B. Levetiracetam is associated with an increased risk of major congenital malformations, particularly neural tube defects, when used during the first trimester. Exposure in the second. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.